03/07/2017 504259501

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT4306181

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
CURELON, LLC	01/13/2017

RECEIVING PARTY DATA

Name:	GALENAGEN, LLC
Street Address:	411 THEODORE FREMD AVE.
Internal Address:	SUITE 206 S.
City:	RYE
State/Country:	NEW YORK
Postal Code:	10580

PROPERTY NUMBERS Total: 14

Property Type	Number
Application Number:	61594015
Application Number:	13757412
Application Number:	61142718
Application Number:	61153279
Application Number:	61170856
Application Number:	14713221
Application Number:	13144290
Application Number:	61142714
Application Number:	61153274
Application Number:	61170915
Application Number:	14713242
Application Number:	13144286
Application Number:	61086136
Application Number:	12535676

CORRESPONDENCE DATA

Fax Number: (858)350-2399

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 8583502300

Email: asgarcia@wsgr.com

Correspondent Name: WILSON SONSINI GOODRICH & ROSATI

Address Line 1: 650 PAGE MILL ROAD

Address Line 4: PALO ALTO, CALIFORNIA 94304

ATTORNEY DOCKET NUMBER:	42354-700
NAME OF SUBMITTER:	ASHLEY GARCIA
SIGNATURE:	/Ashley Garcia/
DATE SIGNED:	03/07/2017

Total Attachments: 7

source=Curelon to Galenagen Assignment#page1.tif source=Curelon to Galenagen Assignment#page2.tif source=Curelon to Galenagen Assignment#page3.tif source=Curelon to Galenagen Assignment#page4.tif source=Curelon to Galenagen Assignment#page5.tif source=Curelon to Galenagen Assignment#page6.tif source=Curelon to Galenagen Assignment#page7.tif

ASSIGNMENT OF PATENTS

This Assignment of Patents is made effective as of January 13, 2017, by Curelon, LLC, a Delaware limited liability company (the "ASSIGNOR"), to and for the benefit of Galenagen, LLC, a Delaware limited liability company with offices at 411 Theodore Fremd Avenue, Suite 206, Rye, New York 10580, and its successors and assigns (the "ASSIGNEE").

WHEREAS, the ASSIGNOR has agreed to sell and ASSIGNEE has agreed to purchase certain assets of the ASSIGNOR pursuant to an Asset Purchase Agreement by and among the ASSIGNOR and the ASSIGNEE dated of even date herewith (the "Asset Purchase Agreement"); and

WHEREAS, the ASSIGNOR is the sole and exclusive owner of the patents and patent applications listed in <u>Schedule A</u> attached hereto (the "<u>Patents</u>") and also of all of the inventions described and claimed therein, including the right to apply for and obtain U.S. and foreign patents on said inventions; and

WHEREAS, the ASSIGNOR has agreed pursuant to the Asset Purchase Agreement to transfer and assign the Patents and the inventions described and claimed therein to the ASSIGNEE as provided herein;

NOW, THEREFORE, for good and valuable consideration received pursuant to the Asset Purchase Agreement, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, ASSIGNOR hereby sells, assigns, transfers and sets over to ASSIGNEE, its successors, assigns and legal representatives, the entire right, title and interest in and throughout the United States of America (including its territories and dependencies) and all countries foreign thereto, in and to and under said Patents and any and all inventions described and/or claimed therein and any and all patents and like rights of exclusion (including reissue, reexamination or extensions thereof) of any country which may be granted on or for said inventions or on any counterpart, divisional, substitution, continuation, continuation-in-part, or other patent application based on said Patents, the same to be held and enjoyed by the ASSIGNEE for its own use and benefit, and for the use and benefit of its successors, assigns or other legal representatives, as fully and entirely as the same would have been held and enjoyed by ASSIGNOR if this assignment had not been made, together with (a) all rights to receive royalties, fees, income, payments, and other proceeds now or hereafter due or payable with respect to any and all of the foregoing, and (b) all claims and causes of action with respect to any of the foregoing, whether accruing before, on, or after the date hereof, including, without limitation, all rights to and claims for damages, restitution, and injunctive and other legal and equitable relief for or by reason of past, present or future infringement of said Patents or said inventions or misuse, misappropriation or theft of any of said inventions, and (c) the right to sue for and collect such damages, restitution, and injunctive and other legal or equitable relief for its own use and benefit, and for the use and benefit of its successors, assigns or other legal representatives.

ASSIGNOR hereby covenants and agrees to cooperate with said ASSIGNEE to enable said ASSIGNEE to enjoy to the fullest extent the right, title and interest herein conveyed in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty. Such cooperation by the ASSIGNOR shall include prompt production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other assistance all to the extent deemed necessary or desirable by the parties (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any of

DM2\7230717.3

said applications covering said Inventions; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said Inventions; (d) for filing and prosecuting applications for reissuance of any said Patent(s); (e) for interference or other priority proceedings involving said Inventions; and (f) for legal proceedings involving said Inventions and any applications therefor and any Patent(s) granted thereon, including without limitation reissues and reexaminations, opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions.

ASSIGNOR also hereby sells, assigns and transfers unto the ASSIGNEE, its successors and assigns, all of its rights under the Paris Convention for the Protection of Industrial Property and all other treaties of like purpose in respect of each and all of said Patents and said inventions and any other patents issued thereon.

ASSIGNOR hereby authorizes the ASSIGNEE, its successors, assigns or other legal representatives to apply in its or their own name or names for patents and like rights of exclusion on or for said inventions or any of them or any part thereof in all countries, claiming if it or they so desire the priority of the filing date under the provisions of said Convention and all such other treaties of like purpose. Assignor further authorizes the Commissioner for Patents in the United States Patent and Trademark Office and the officials of corresponding entities or agencies in any other applicable jurisdictions to record and register this Patent Assignment upon request by Assignee.

ASSIGNOR hereby request that any Patent(s) issuing in the United States, foreign countries, or under any international convention, agreement, protocol, or treaty, be issued in the name of the ASSIGNEE, or its successors and assigns, for the sole use of said ASSIGNEE its successors, legal representatives and assigns.

This Assignment of Patents is delivered pursuant to, and subject to, the terms and conditions of the Asset Purchase Agreement. Nothing contained in this Assignment of Patents shall be deemed to supersede any of the representations, warranties, covenants or other agreements contained in the Asset Purchase Agreement or otherwise expand any of the rights or remedies of the ASSIGNEE with respect to the transactions contemplated thereby. To the extent any of the provisions in this Assignment of Patents are inconsistent with the Asset Purchase Agreement, the Asset Purchase Agreement shall control.

SIGNATURE PAGE FOLLOWS

DM2\7230717.3

IN WITNESS WHEREOF, ASSIGNOR at Patents effective as of the day of January, 201	nd ASSIGNEE have executed this Assignment of 7
CURELON, LLC	GALENAGEN, LLC
	By: Curemark, LLC, its sole Member
By: Name: Joan Fallon	By: Name: Jzaneen Lajani Title Ghi 600 di 0000
Title: Chief/Executive Officer	Title: Chief Operating Officer
STATE OF NEW YORK: COUNTY OF Westers	SS.
I, Margaret I for Si County aforesaid, do hereby certify that on this da personally known, who, being by me duly sworn, Curelon, LLC, and that said instrument was signed instrument to be the free act and deed of said entit	did say that she is the Chief Executive Officer of don behalf of said corporation and said
Subscribed and sworn to before me	this day of January, 2017.
My commission expires:	Notary Public
STATE OF NEW YORK: COUNTY OF Westernest:	MARGARET DAMBROSIO NOTARY PUBLIC-STATE OF NEW YORK No. 01DA6118732 Qualified In Westchester County SS. My Commission Expires 11-15-2020
County aforesaid, do hereby certify that on this da personally known, who, being by me duly sworn,	did say that she is the Chief Operating Officer of enagen, LLC, and that said instrument was signed
Subscribed and sworn to before me	e this day of January, 2017.
My commission expires:	Notary Public '
	MARGARET DAMBROSIO NOTARY PUBLIC-STATE OF NEW YORK

No. 01DA6118732
Qualified In Westchester County
My Commission Expires 11-15-2020
PATENT

REEL: 041483 FRAME: 0600

CURELON, LLC ASSIGNMENT OF PATENTS

Schedule A Patent Applications and Issued Patents

701 Family: ENZYME COMPOSITIONS AND USE THEREOF FOR WOUND HEALING

Country	==App. No.	Filing Date:	Patent No.	Issue Date
United States of America	61/594,015	02-Feb-2012		
United States of America	13/757,412	01-Feb-2013		
Patent Cooperation Treaty	PCT/US2013/024453	01-Feb-2013		
European Patent Convention	13743239.9	01-Feb-2013		
Canada	2,862,363	01-Feb-2013		
China (People's Republic)	201380018617.X	01-Feb-2013		
Hong Kong	15103825.8	01-Feb-2013		

702 Family: COMPOSITIONS AND METHODS FOR THE TREATMENT OR THE PREVENTION OF E. COLI INFECTIONS AND FOR THE ERADICATION OR REDUCTION OF E. COLI SURFACES

Country	App. No.	Filing Date	Patent No.	Issue Date:
Australia	2010203714	06-Jan-2010	2010203714	28-Nov-2013
Brazil	PI1007379-5	06-Jan-2010		
Canada	2,747,703	06-Jan-2010		
China (People's Republic)	201080004044.1	06-Jan-2010	ZL201080004044.1	12-Aug-2015
China (People's Republic)	201510419796.9	06-Jan-2010		
European Patent Convention	10729467.0	06-Jan-2010		
European Patent Convention	15152332.1	06-Jan-2010		

DM3\4414862;2

Country	App. No.	Filing Date	Patent No.	Issue Date
Hong Kong	12102871.6	06-Jan-2010		
Hong Kong	16104669.4	06-Jan-2010		
Hong Kong	16105287.3	06-Jan-2010		
India	2482/KOLNP/2011	1.6.2010		
Israel	213489	06-Jan-2010		
Israel	240098	06-Jan-2010		
Japan	2011-544678	06-Jan-2010		
Japan	2015-084102	06-Jan-2010		
Korea, Republic of	10-2011-7018328	06-Jan-2010		
Korea, Republic of	10-2017-7000179	06-Jan-2010		
Macau	J/001926	06-Jan-2010	J/001926	24-Feb-2016
New Zealand	593823	06-Jan-2010	593823	07-Jan-2014
Patent Cooperation Treaty	US2010/20259	06-Jan-2010		
South Africa	2011/04482	06-Jan-2010		
United Kingdom	1111566.4	06-Jan-2010	2480773	11-Dec-2013
United States of America	61/142,718	06-Jan-2009		
United States of America	61/153,279	17-Feb-2009		
United States of America	61/170,856	20-Apr-2009		
United States of America	14/713,221	15-May-2015		
United States of America	13/144,290	12-Jul-2011	9,084,784	21-Jul-2015

703 Family: COMPOSITIONS AND METHODS FOR TREATMENT OR PREVENTION OF STAPHYLOCOCCUS AUREUS INFECTIONS AND FOR THE ERADICATION OR REDUCTION OF STAPHYLOCOCCUS AUREUS ON SURFACES

Country	App. No.	Filing Date	Patent No.	Issue Date
Australia	2010203709	06-Jan-2010	2010203709	04-Sep-2014
Australia	2014213477	06-Jan-2010	2014213477	11-Feb-2016
Australia	2015252099	06-Jan-2010		
Brazil	Pl1007378-7	06-Jan-2010		
Canada	2,747,611	06-Jan-2010		
China (People's Republic)	201080004045.6	06-Jan-2010	ZL 2010800040456	09-Dec-2015
China (People's Republic)	201510735953.7	06-Jan-2010		
European Patent Convention	10729462.1	06-Jan-2010	2373791	30-Mar-2016
European Patent Convention	15200616.9	06-Jan-2010		
France	10729462.1	06-Jan-2010	2373791	30-Mar-2016
Germany	10729462.1	06-Jan-2010	2373791	30-Mar-2016
Hong Kong	12102872.5	06-Jan-2010	1162586B	28-Oct-2016
Hong Kong	16114244.7	06-Jan-2010		
India	2494/KOLNP/11	06-Jan-2010		
Ireland	10729462.1	06-Jan-2010	2373791	30-Mar-2016
Israel	213528	06-Jan-2010	213528	01-Sep-2016
Italy	10729462.1	06-Jan-2010	2373791	30-Mar-2016
Japan	2011-544675	06-Jan-2010	5684725	23-Jan-2015
Japan	2015-005797	06-Jan-2010	603341	04-Nov-2016
Japan	2016-208296	06-Jan-2010		_

3

Country	App. No.	- Filing Date	Patent No.	Issue Date
Korea, Republic of	10-2011-7018327	06-Jan-2010		
Korea, Republic of	10-2017-7000180	06-Jan-2010		
Macau	J/002073	06-Jan-2010	J/002073	23-Jun-2016
Macau	J/002438	14-Dec-2016		
New Zealand	593831	06-Jan-2010	593831	07-Jan-2014
Patent Cooperation Treaty	US2010/20253	06-Jan-2010		
South Africa	2011/04481	06-Jan-2010		
Spain	10729462.1	06-Jan-2010	2373791	30-Mar-2016
Switzerland	10729462.1	06-Jan-2010	2373791	30-Mar-2016
Turkey	10729462.1	06-Jan-2010	TR 2016 08753 T4	30-Mar-2016
United Kingdom	1111565.6	06-Jan-2010	2480772	16-Oct-2013
United Kingdom	10729462.1	06-Jan-2010	2373791	30-Mar-2016
United States of America	61/142,714	06-Jan-2009		
United States of America	61/153,274	17-Feb-2009		
United States of America	61/170,915	20-Apr-2009		
United States of America	14/713,242	15-May-2015		
United States of America	13/144,286	12-Jul-2011	9,107,419	18-Aug-2015

704 Family:

Country	App. No.	Filing Date	Patent No.	Issue Date
United States of America	61/086,136	04-Aug-2008		
United States of America	12/535,676	04-Aug-2009		

4

RECORDED: 03/07/2017